Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Suvretta Capital Management LLC

Suvretta Capital Management LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,019,000 shares of the biopharmaceutical company’s stock after selling 259,000 shares during the quarter. Ultragenyx Pharmaceutical makes up approximately 1.6% of Suvretta Capital Management LLC’s holdings, making the stock its 22nd largest holding. Suvretta Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $60,732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of RARE. Norges Bank purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth approximately $35,765,000. Hsbc Holdings PLC increased its holdings in shares of Ultragenyx Pharmaceutical by 88.6% during the 2nd quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 45,665 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Ultragenyx Pharmaceutical by 108.1% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 35,185 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock worth $35,768,000 after buying an additional 325,000 shares during the period. Finally, Schroder Investment Management Group boosted its holdings in Ultragenyx Pharmaceutical by 27.2% in the second quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after acquiring an additional 71,888 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $21.34 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $42.37. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -3.65 and a beta of 0.16. The business has a 50-day moving average of $23.01 and a 200-day moving average of $28.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.39) earnings per share. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RARE has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday. Guggenheim decreased their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a report on Monday, January 5th. Wedbush reissued a “neutral” rating and set a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Canaccord Genuity Group cut their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Finally, Barclays reduced their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, November 24th. Sixteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $65.76.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 1,632 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $37,209.60. Following the completion of the transaction, the chief accounting officer directly owned 48,670 shares in the company, valued at approximately $1,109,676. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 8,135 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.